NEW YORK, June 6, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please
scroll to bottom.
Today, Wall Street Reports announced new research reports
highlighting Clovis Oncology Inc. (NASDAQ: CLVS), MannKind
Corporation (NASDAQ: MNKD), TESARO Inc. (NASDAQ: TSRO), Peregrine
Pharmaceuticals (NASDAQ: PPHM), and Vanda Pharmaceuticals Inc.
(NASDAQ: VNDA). Today's readers may access these reports free of
charge - including full price targets, industry analysis and
analyst ratings - via the links below.
Clovis Oncology Inc. Research
Report
On June 3, 2013, Clovis Oncology
Inc. (Clovis Oncology) announced initial findings from the Phase I
portion of its ongoing Phase I/II clinical study of CO-1686, the
novel, oral, targeted covalent (irreversible) inhibitor of mutant
forms of the epidermal growth factor receptor (EGFR) for the
treatment of non-small cell lung cancer (NSCLC) in patients with
initial activating EGFR mutations as well as the dominant
resistance mutation T790M. According to the Company, three of four
evaluable T790M patients treated at 900mg BID (twice-daily)
achieved partial responses. Further, it reported that CO-1686
appeared well-tolerated, with no evidence of wild-type EGFR
inhibition. Dr. Lecia V. Sequist of
the Massachusetts General Hospital Cancer Center and Associate
Professor of Medicine at Harvard Medical
School, Boston, said, "It
has been exciting and quite hopeful to observe that patients are
responding to CO-1686 and that the side effect profile has been so
mild. A drug that works effectively for EGFR acquired resistance
would be welcomed by the lung cancer community." The Full Research
Report on Clovis Oncology Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free
of charge at:
[http://www.wsreports.com/r/full_research_report/6b27_CLVS]
--
MannKind Corporation Research
Report
On May 31, 2013, MannKind
Corporation (MannKind) announced that all follow-up visits have
been completed for patients enrolled in Study 171, a Phase 3
clinical study of AFREZZA (insulin human [rDNA origin]) inhalation
powder, an investigational, ultra rapid-acting mealtime insulin
therapy, administered using the Company's next-generation inhaler.
Study 171 is an open-label study in patients with type 1 diabetes.
After a run-in period, during which all patients were optimized on
their basal insulin regimen, 518 subjects were randomized to one of
three arms for mealtime insulin: a control arm, in which patients
utilize rapid-acting insulin, or one of two AFREZZA arms, one for
the MedTone inhaler and the other for the next-generation inhaler.
After the mealtime insulin was titrated, there was a 12-week
observation period on stable doses of the mealtime insulin to
assess HbA1c levels, which is the primary outcome parameter. The
Company expects to release data from this study in the summer of
2013. The Full Research Report on MannKind Corporation - including
full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/0b44_MNKD]
--
TESARO Inc. Research Report
On June 3, 2013, TESARO, Inc.
(TESARO), Breast International Group (BIG), a non-profit
organization for academic breast cancer research groups from around
the world, and the European Organization for Research and Treatment
of Cancer (EORTC), an international, independent, multidisciplinary
non-profit research organization, announced a partnership for the
Phase 3 clinical development of niraparib, an orally active, potent
poly (ADP-ribose) polymerase (PARP) inhibitor. TESARO, BIG and
EORTC will use BIG's and EORTC's scientific and clinical expertise
and network of collaborative groups and their associated hospitals
and oncology research centers to accelerate the completion of the
Phase 3 clinical trial of niraparib in patients with breast cancer.
The primary endpoint of this trial is progression free survival
(PFS), with overall survival (OS) as a secondary endpoint. TESARO
expects to open this study to patients during the second half of
2013. The Full Research Report on TESARO Inc. - including full
detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/4f59_TSRO]
--
Peregrine Pharmaceuticals Research
Report
On June 3, 2013, Peregrine
Pharmaceuticals, Inc. (Peregrine Pharmaceuticals) reported that
data was presented at the 2013 ASCO (American Society of Clinical
Oncology) Meeting from two clinical trials evaluating the Company's
lead clinical candidate bavituximab, a first-in-class
phosphatidylserine (PS)-targeting monoclonal antibody that
represents a new approach to treating cancer. Interim data from a
Phase I trial, evaluating bavituximab plus paclitaxel therapy in
patients with HER2-negative metastatic breast cancer (MBC), showed
that 85% of patients were able to achieve objective tumor response,
with 15% of patients achieving a complete response (CR) in
accordance to Response Evaluation Criteria in Solid Tumors
(RECIST). Further, the Company reported that in the second study,
results from a randomized Phase II trial of bavituximab plus
gemcitabine in patients with non-resectable Stage IV pancreatic
cancer demonstrated more than a doubling of the overall response
rate (ORR) and an improvement in overall survival (OS), including a
delayed separation in the Kaplan-Maeier survival curve that is
commonly seen in promising cancer immunotherapies. The Full
Research Report on Peregrine Pharmaceuticals - including full
detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/df4a_PPHM]
--
Vanda Pharmaceuticals Inc. Research
Report
On May 31, 2013, Vanda
Pharmaceuticals Inc. (Vanda Pharmaceuticals) announced the
submission of a New Drug Application (NDA) to the U.S. Food and
Drug Administration (FDA) for tasimelteon, a circadian regulator in
development for the treatment of non-24 hour disorder (Non-24) in
the totally blind. Non-24 is a serious and rare, circadian rhythm
disorder that affects the majority of totally blind individuals who
lack light perception and, therefore, cannot synchronize their
master body clock to the 24-hour day. There are currently no FDA
approved products for the treatment of Non-24. The Full Research
Report on Vanda Pharmaceuticals Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.wsreports.com/r/full_research_report/b7a8_VNDA]
----
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by a CFA. However, we are only
human and are prone to make mistakes. If you notice any errors or
omissions, please notify us below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquires, please contact us
at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research@EquityNewsNetwork.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Equity News Network. An outsourced research services provider has,
through Chartered Financial Analysts, only reviewed the information
provided by Equity News Network in this article or report according
to the Procedures outlined by Equity News Network. Equity News
Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as
to the accuracy or completeness or fitness for a purpose
(investment or otherwise), of the information provided in this
document. This information is not to be construed as personal
financial advice. Readers are encouraged to consult their personal
financial advisor before making any decisions to buy, sell or hold
any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may
be occasioned at the time of printing of this document or any
error, mistake or shortcoming. No liability is accepted by Equity
News Network whatsoever for any direct, indirect or consequential
loss arising from the use of this document. Equity News Network
expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance
placed on the information in this document. Equity News Network
does not (1) guarantee the accuracy, timeliness, completeness or
correct sequencing of the information, or (2) warrant any results
from use of the information. The included information is subject to
change without notice.
SOURCE Wall Street Reports